Brokerage firm Brean Capital Assumes its rating on Alder Biopharmaceuticals Inc(NASDAQ:ALDR). The shares have been rated Buy. The rating by Brean Capital was issued on Sep 30, 2016.
In a different note, JP Morgan said it Initiates Coverage on Alder Biopharmaceuticals Inc, according to a research note issued on Sep 13, 2016. The shares have been rated ‘Overweight’ by the firm. On Jul 27, 2016, Jefferies said it Maintains its rating on Alder Biopharmaceuticals Inc. In the research note, the firm Raises the price-target to $61.00 per share. The shares have been rated ‘Buy’ by the firm.
Alder Biopharmaceuticals Inc (ALDR) shares turned negative on Tuesdays trading session with the shares closing down -0.3 points or -0.96% at a volume of 2,89,380. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $31.71. The peak price level was also seen at $31.71 while the days lowest was $30.65. Finally the shares closed at $31.08. The 52-week high of the shares is $39.43 while the 52-week low is $15.8201. According to the latest information available, the market cap of the company is $1,560 M.
Alder Biopharmaceuticals Inc(ALDR) last announced its earnings results on Jul 26, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $113.00K. Analysts had an estimated revenue of $1.14M. Earnings per share were $-0.79. Analysts had estimated an EPS of $-0.75.
Several Insider Transactions has been reported to the SEC. On Sep 6, 2016, John A Latham (Chief Scientific Officer) sold 10,000 shares at $32.49 per share price.Also, On Sep 6, 2016, Randall C Schatzman (President and CEO) sold 10,000 shares at $32.48 per share price.On Sep 6, 2016, Jeffrey T L Smith (Sr. VP Translational Medicine) sold 3,000 shares at $32.79 per share price, according to the Form-4 filing with the securities and exchange commission.
Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company discovers develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response. The Company’s pipeline includes ALD403 Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6) and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH) and is being developed for the treatment of Cushing’s disease.